Systematic Treatment of Central Retinal Vein Occlusion

Background

Central retinal vein occlusion (CRVO), a common cause of visual loss, is a prevalent retinal vascular disease that is often associated with a variety of systemic conditions and concern in 90 % of cases, patients over the age of 50 years. Bilateral CRVO in young adults is a rare presenting feature.

We report the case of a 51-year-old man, who presented with an ischemic CRVO of the right eye (RE) followed 8 months later by ischemic CRVO of the left eye (LE), which was treated aggressively and led to preservation of LE visual acuity.

• References

• 1 Hayreh SS, Fraterrigo L, Jonas J. Central retinal vein occlusion associated with cilioretinal artery occlusion. Retina 2008; 28: 581-594
• 2 Glueck CJ, Hutchins RK, Jurantee J et al. Thrombophilia and retinal vascular occlusion. Clin Ophthalmol 2012; 6: 1377-1384
• 3 Mruthyunjaya P, Wirostko WJ, Chandrashekhar R et al. Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation. Retina 2006; 26: 285-291
• 4 Donati G, Mavrakanas N, Pournaras CJ. [Isovolemic hemodilution in the management of the acute phase of central retinal vein occlusion: a pilot study]. J Fr Ophtalmol 2009; 32: 750-756
• 5 Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol 2010; 4: 809-816
• 6 Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 2011; 118: 119-133.e1-2
• 7 Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 336-339
• 8 Varma R, Bressler NM, Suñer I et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 2012; 119: 2108-2118
• 9 Gregori NZ, Gaitan J, Rosenfeld PJ et al. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina 2008; 28: 1325-1337
• 10 Kim NR, Chin HS. Progression of impending central retinal vein occlusion to the ischemic variant following intravitreal bevacizumab. Korean J Ophthalmol 2010; 24: 179-181